Dual-targeted NIR-II AIE theranostic nanoparticles disrupt HNRNPC-driven ITGA1+ myCAFs differentiation and immune evasion in oral squamous cell carcinoma
Source abstract
Abstract
Oral squamous cell carcinoma (OSCC) remains a therapeutic challenge due to its aggressive metabolism-driven progression and immunosuppressive tumor microenvironment (TME). Through proteomic and transcriptomic analyses, we identified HNRNPC as a novel driver of OSCC progression via aberrant glycolysis and TGF-β-mediated differentiation of ITGA1+ myofibroblastic cancer-associated fibroblasts (myCAFs), which directly induce CD8+ T cell exhaustion. Given the lack of strategies that simultaneously target both tumor and stromal compartments, we engineered a theranostic solution: Near-infrared-II (NIR-II) imaging-guided aggregation-induced emission nanoparticles (AIE NPs) dually conjugated with antibodies against HNRNPC and ITGA1 (NPs-H-I). Studies using molecular experiments, single-nucleus sequencing (snRNA-seq), allograft models, and clinical specimens confirmed that HNRNPC-high OSCCs are enriched with ITGA1+ myCAFs and exhausted CD8+ T cells, correlating with poor patient survival. The developed NPs-H-I demonstrated specific accumulation in tumors, enabling precise NIR-II imaging. Upon 808 nm laser irradiation, NPs-H-I elicited potent photodynamic therapy (PDT), selectively eliminating HNRNPC-high tumor cells and ITGA1+ myCAFs, which robustly inhibited tumor growth and restored anti-tumor immunity in murine models. Our work not only delineates the HNRNPC-ITGA1 axis as a novel metabolic-immune checkpoint in OSCC but also establishes a versatile and translatable precision medicine platform capable of disrupting this pathway for effective combination therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Cells and Metastasis · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (43)
Show source-provided references
1. Oral cancer: etiology and risk factors: a review10.4103/0973-1482.186696 ↗
2. Oral cancer: genetics and the role of precision medicine10.1016/j.soc.2019.08.010 ↗
3. "Omics" in oral cancer: new approaches for biomarker discovery10.1016/j.archoralbio.2017.12.003 ↗
4. Hallmarks of cancer: new dimensions10.1158/2159-8290.CD-21-1059 ↗
5. The hallmarks of cancer metabolism: still emerging10.1016/j.cmet.2022.01.007 ↗
6. (mt), and the complexity of mitochondrial DNA landscapes in cancer10.1158/0008-5472.CAN-19-1395 ↗
7. Mitohormesis primes tumor invasion and metastasis10.1016/j.celrep.2019.04.095 ↗
8. lncRNA CYTOR promotes aberrant glycolysis and mitochondrial respiration via HNRNPC-mediated ZEB1 stabilization in oral squamous cell carcinoma10.1038/s41419-022-05157-1 ↗
9. Metabolic barriers to cancer immunotherapy10.1038/s41577-021-00541-y ↗
10. Influence of tumour micro-environment heterogeneity on therapeutic response10.1038/nature12626 ↗
11. Foxp3 Reprograms T cell metabolism to function in Low-Glucose, high-lactate environments10.1016/j.cmet.2016.12.018 ↗
12. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer10.1016/j.cmet.2018.04.022 ↗
13. Cancer: an oxidative crosstalk between solid tumor cells and cancer associated fibroblasts10.1155/2016/4502846 ↗
14. The biology and function of fibroblasts in cancer10.1038/nrc.2016.73 ↗
15. Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins10.1016/j.semcancer.2019.08.004 ↗
16. The matrix in cancer10.1038/s41568-020-00329-7 ↗
17. A framework for advancing our understanding of cancer-associated fibroblasts10.1038/s41568-019-0238-1 ↗
18. TGF-β and the tissue microenvironment: relevance in fibrosis and cancer10.3390/ijms19051294 ↗
19. Targeting integrin pathways: mechanisms and advances in therapy10.1038/s41392-022-01259-6 ↗
20. Myofibroblast TGF-β activation measurement in vitro10.1007/978-1-0716-1382-5_6 ↗
21. CD8(+) T cell differentiation and dysfunction in cancer10.1038/s41577-021-00574-3 ↗
22. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy10.1038/s41416-020-01048-4 ↗
23. PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8(+) T cell exhaustion during metastasis10.1111/cas.15033 ↗
24. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients10.1172/JCI46102 ↗
25. Photodynamic therapy of cancer: an update
26. Harnessing the power of aggregation-induced emission luminogens: From bright probes to theranostic platforms in biomedicine10.1016/j.ccr.2025.217553 ↗
27. Aggregation-Induced emission (AIE), life and health10.1021/acsnano.3c03925 ↗
28. Aggregation-Induced emission nanoparticles for single near-infrared light-triggered photodynamic and photothermal antibacterial therapy10.1021/acsnano.2c00734 ↗
29. TGF-β signaling in the tumor metabolic microenvironment and targeted therapies10.1186/s13045-022-01349-6 ↗
30. TGF-β links glycolysis and immunosuppression in glioblastoma
31. Neglected, yet significant role of FOXP1 in T-cell quiescence, differentiation and exhaustion10.3389/fimmu.2022.971045 ↗
32. Molecular and cellular insights into T cell exhaustion10.1038/nri3862 ↗
33. Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression10.1016/j.immuni.2014.08.012 ↗
34. The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: a systematic review and meta-analysis10.1002/cam4.2510 ↗
35. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials10.1177/1758835920937612 ↗
36. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions10.1186/s12943-021-01489-2 ↗
37. Rhythmic mild photothermal therapy enhancing anti-PD-L1 response for oral squamous cell carcinoma immunotherapy10.1016/j.cej.2024.150908 ↗
38. Recent advances in aggregation-induced emission materials and their biomedical and healthcare applications10.1002/adhm.202101055 ↗
39. Brain-Targeted aggregation-induced-emission nanoparticles with near-infrared imaging at 1550 nm boosts orthotopic glioblastoma theranostics10.1002/adma.202106082 ↗
40. Powerful synergy of traditional Chinese medicine and aggregation-induced emission-active photosensitizer in photodynamic therapy10.1021/acsnano.3c04342 ↗
41. Structure and functions of Aggregation-Induced Emission-Photosensitizers in anticancer and antimicrobial theranostics10.3389/fchem.2022.984268 ↗
42. The genome sequence archive family: toward explosive data growth and diverse data types10.1016/j.gpb.2021.08.001 ↗
43. Database resources of the National Genomics Data Center, China National Center for bioinformation in 202210.1093/nar/gkab951 ↗